Serum Triglycerides Are Related to Chronic Kidney Disease (CKD) Stage 2 in Young and Middle-Aged Chinese Individuals During Routine Health Examination

AEF Ning Xue  
CEF Yi Fang  
BC Xiaoqiang Ding  
DF Li Wang  
BD Linghan Xu  
AD Xiaotian Jiang  
CDF Xiaoyan Zhang

Corresponding Authors: Yi Fang, e-mail: fang.yi@zs-hospital.sh.cn, Xiaoqiang Ding, e-mail: ding.xiaoqiang@zs-hospital.sh.cn

Source of support: This work was supported by the Science and Technology Commission of Shanghai Municipality (14DZ2260200, the project of Shanghai Key Laboratory of Kidney and Blood Purification) and Shanghai Municipal Commission of Health and Family Planning (2017ZZ01015, the project of Shanghai Clinical Medical Center)

Background: The aim of this study was to determine the risk factors for early chronic kidney disease (CKD) (GFR 60–89 ml/min/1.73 m²; CKD stage 2) in asymptomatic Chinese individuals undergoing routine health examination.

Material/Methods: This cross-sectional study enrolled 9100 individuals who received voluntary medical examinations between 10/01/2011 and 09/30/2017. Demographic data, clinical history, clinical examination, medication, smoking, alcohol, blood biochemistry, urinalysis, and carotid ultrasound were extracted from the medical records. All laboratory analyses were performed routinely. Multivariable logistic regression for factors predicting CKD stage 2 was performed.

Result: A total of 9100 individuals were enrolled (age of 18-65 and 65.4% male). CKD stage 2 was found in 1989/9100 individuals (21.9%). Male gender (OR=6.711, 95%CI: 5.376–8.403, P<0.001), older age (OR=1.077, 95%CI: 1.068–1.086, P<0.001), hemoglobin levels (OR=1.051, 95%CI: 1.046–1.057, P<0.001), triglycerides levels (OR=1.174, 95%CI: 1.067–1.292, P=0.001), HDL-C (OR=0.539, 95%CI: 0.380–0.763, P<0.001), Lp(a) levels (OR=1.000, 95%CI: 1.000–1.001, P=0.03), and carotid atherosclerosis (OR=1.248, 95%CI: 1.005–1.550, P=0.045) were associated with CKD stage 2 among all subjects. Serum triglycerides levels were associated with CKD stage 2 in the 18-45 and 45-65 years of age subgroups.

Conclusions: Factors that are routinely assessed during routine health examinations (male gender, age, hemoglobin levels, triglycerides levels, HDL-C, Lp(a) levels, and carotid atherosclerosis) can help identify individuals at higher risk of having CKD stage 2. The Chinese dyslipidemia is characterized by high triglycerides and low HDL-C and occurs in young and middle-aged individuals. Those factors could help identify individuals at higher risk for CKD stage 2 and who could benefit from preventive treatments.

MeSH Keywords:  
Fontan Procedure • Renal Insufficiency, Chronic • Risk Factors

Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/913506
Background

Chronic kidney disease (CKD) is characterized by abnormalities of kidney structure or function that have been present for >3 months and have implications for health [1]. CKD can be defined based on the glomerular filtration rate (GFR) and CKD is defined as GFR <60 ml/min/1.73 m$^2$ (or stage >3) [1]. The prevalence of stage 3–5 CKD is 7–15% worldwide [2]. In China, the prevalence of CKD is 10.8% [2,3], roughly representing over 100 million patients, imposing a serious burden to the health care system and society and reduced quality of life [4].

Stage 2 CKD (GFR 60–89 ml/min/1.73 m$^2$), although non-clinically significant in the absence of other pathological signs of CKD [1], can suggest the beginning of the disease process. Since therapies are available to slow the progression of CKD stage 2 to advanced stages requiring dialysis or kidney transplantation, early management can improve patient prognosis, with reduced morbidity and mortality [5–7].

The main issue is how to predict CKD stage 2 in patients who are asymptomatic and who only undergo routine clinical examinations. Indeed, any disease screening process has to balance optimal disease detection with costs and inconvenience to the individuals. A number of programs are available worldwide [8–10], but they require formal settings and processes, or target high-risk populations. Optimal screening should be automatic and based on routine parameters that are readily available and obtained during routine health examinations [11]. A number of studies examined predictive factors and models for CKD stage 2 in various populations [12–20]. Nevertheless, since CKD is related to environmental factors such as diet, stress, and population [21,22], population-specific studies are necessary to identify the factors adequately. The main manifestation of dyslipidemia in China is high triglycerides and low high-density lipoprotein cholesterol (HDL-C) levels [23–25]. The Chinese diet has been associated with high blood triglycerides levels [26]. In Asian countries such as Japan, hypertriglyceridemia and low HDL-C are associated with the decline of GFR [27–29]. Carotid atherosclerosis is a marker of the cardiovascular risk associated with high triglycerides and low HDL-C, and has also been associated with GFR decline [30,31].

Therefore, the aim of the present study was to determine the risk factors for CKD stage 2 (GFR 60–89 ml/min/1.73 m$^2$) in asymptomatic Chinese individuals undergoing routine health examination.

Material and Methods

Study design and patients

This was a cross-sectional study of people who received voluntary medical examinations between October 1st, 2011 and September 30th, 2017. This study was approved by the ethics committee of our hospital. All subjects provided a written informed consent.

The inclusion criteria were: 1) 18–65 years of age; 2) voluntarily received physical examination; and eGFR >60 ml/min/1.73 m$^2$. The exclusion criteria were: 1) refused to provide medical history; 2) acute and active infection within 1 week of the physical examination; 3) women during menstrual period; 4) pregnant or lactating; 5) acute cardiac insufficiency, acute or chronic respiratory failure, or acute kidney injury; 6) cancer; 7) life expectancy <12 months; or 8) severe mental disorders.

Data collection

Demographic data, clinical history, clinical examination, medication, smoking, drinking, urinalysis, and carotid ultrasound were extracted from the patient charts. All laboratory analyses were performed routinely. Blood pressure was measured after a 10-min rest in the sitting position; both arms were measured and the highest value was kept. eGFR was calculated using the Modification of Diet in Renal Disease equation, modified for Chinese individuals [32,33].

Statistical analysis

Continuous data were tested for normal distribution with the Kolmogorov-Smirnov test and presented as means ± standard deviation or median (range), as appropriate, and analyzed using the Student t test or the Mann-Whitney U test. Categorical data were presented as frequencies and analyzed using the chi-square test. Multivariate logistic regression for factors predicting stage 2 CKD was performed using the enter method. SPSS 16.0 (IBM, Armonk, NY, USA) was used for analysis. Two-sided P-values <0.05 were considered statistically significant.

Results

Characteristics of the subjects

A total of 10,277 individuals were screened for eligibility and 9100 finally met the eligibility criteria: 1989 with eGFR 60–89 ml/min/1.73 m$^2$ and 7111 with normal renal function (eGFR >90 ml/min/1.73 m$^2$). Table 1 presents the characteristics of the patients. Compared with individuals with normal eGFR, those with CKD stage 2 showed a lower frequency of male,
older age, and higher frequencies of hypertension, history of cardiovascular disease, history of cancer, and negative hematuria. The levels of hemoglobin, uric acid, total cholesterol, triglycerides, and low-density lipoprotein cholesterol (LDL-C) were higher in the eGFR 60–89 ml/min/1.73 m² group compared with the eGFR >90 ml/min/1.73 m² group, while HDL-C and the frequency of hematuria were lower.

Related factors to CKD stage 2

Table 2 shows that male gender, older age, hemoglobin levels, triglycerides levels, HDL-C, Lp(a) levels, and carotid atherosclerosis were associated with eGFR 60–89 ml/min/1.73 m² among all subjects.

Predictive factors for CKD stage 2 in males

Table 3 shows that age, history of hypertension, hemoglobin levels, and triglycerides levels were associated with eGFR 60–89 ml/min/1.73 m² among males.

Table 1. Characteristics of the subjects.

| Baseline data                          | eGFR 60–89 ml/min/1.73 m² (n=1989) | eGFR >90 ml/min/1.73 m² (n=7111) | P   |
|----------------------------------------|-----------------------------------|----------------------------------|-----|
| Gender, Male, n (%)                    | 1050 (52.8)                       | 4902 (68.9)                      | <0.001 |
| Age (years)                            | 48.00 [21.00–60.00]               | 45.00 [18.00–60.00]              | <0.001 |
| History of hypertension, n (%)         | 537 (27.0)                        | 1621 (22.8)                      | <0.001 |
| History of diabetes mellitus, n (%)    | 210 (10.6)                        | 752 (10.6)                       | 0.983  |
| History of coronary heart disease or stroke, n (%) | 138 (6.9) | 400 (5.6) | 0.028 |
| History of chronic kidney disease, n (%) | 95 (4.8) | 337 (4.7) | 0.945 |
| History of cancer, n (%)               | 62 (3.1)                          | 139 (2.0)                        | 0.002  |
| Body mass index (kg/m²)                | 24.28 [14.86–42.41]               | 24.44 [14.33–45.52]              | 0.091  |
| Hemoglobin (g/L)                       | 150.00 [81.00–194.00]             | 142.00 [63.00–207.00]            | <0.001 |
| Proteinuria, n (%)                     | 33 (1.7)                          | 141 (2.0)                        | 0.351  |
| Hematuria, n (%)                       | 64 (3.2)                          | 400 (5.6)                        | <0.001 |
| Blood uric acid (µmol/L)               | 389.00 [124.00–821.00]            | 331.00 [100.00–716.00]           | <0.001 |
| Total cholesterol (mmol/L)             | 4.84 [1.90–11.17]                 | 4.72 [1.83–14.70]                | <0.001 |
| Triglycerides (mmol/L)                 | 1.61 [0.40–16.23]                 | 1.42 [0.31–21.56]                | <0.001 |
| High-density lipoprotein cholesterol (mmol/L) | 1.14 [0.38–3.15] | 1.22 [0.28–10.70] | <0.001 |
| Low-density lipoprotein cholesterol (mmol/L) | 2.82 [0.33–8.64] | 2.68 [0.35–8.02] | <0.001 |
| Lipoprotein (a) (mg/dL)                | 124.00 [0.00–2534.00]             | 119.00 [0.00–4643.00]            | 0.324  |
| Carotid atherosclerosis, n (%)         | 172 (8.6)                         | 580 (8.2)                        | 0.482  |

Predictive factors for CKD stage 2 in females

Table 3 shows that age, hemoglobin levels, triglycerides levels, HDL-C, and Lp(a) levels were associated with eGFR 60–89 ml/min/1.73 m² among females.

Predictive factors for CKD stage 2 in individuals 18–45 years of age

Table 4 shows that male gender and triglycerides levels were associated with eGFR 60–89 ml/min/1.73 m² among individuals 18–45 years of age.

Predictive factors for CKD stage 2 in individuals 45–65 years of age

Table 4 shows that male gender, carotid atherosclerosis, and triglycerides levels were associated with eGFR 60–89 ml/min/1.73 m² among individuals 45–65 years of age.
Discussion

A number of studies examined the predictive factors and models for CKD stage 2 (GFR 60–89 ml/min/1.73 m²) in various populations [12–20], but they are still controversial. Therefore, this study aimed to determine the risk factors for CKD stage 2 in asymptomatic Chinese individuals undergoing routine health examination. The results suggest that demographic, clinical, and laboratory factors may play a significant role in the development of CKD stage 2.

Table 2. Logistic regression analysis of factors predicting for eGFR of 60–89 ml/min/1.73 m².

| Variables                              | OR    | 95% CI       | P       |
|----------------------------------------|-------|--------------|---------|
| Male                                   | 6.711 | 5.376–8.403  | <0.001  |
| Older age                              | 1.077 | 1.068–1.086  | <0.001  |
| History of hypertension (yes vs. no)   | 1.049 | 0.873–1.26   | 0.609   |
| History of diabetes mellitus (yes vs. no) | 0.863 | 0.691–1.078  | 0.194   |
| History of coronary heart disease or stroke (yes vs. no) | 1.057 | 0.836–1.338  | 0.642   |
| History of cancer (1=yes vs. 0=no)     | 1.074 | 0.747–1.544  | 0.702   |
| Body mass index                        | 1.046 | 0.868–1.26   | 0.639   |
| Systolic blood pressure (high vs. normal) | 1.069 | 0.793–1.441  | 0.662   |
| Diastolic blood pressure (high vs. normal) | 1.052 | 0.753–1.47   | 0.768   |
| Triglycerides                          | 1.174 | 1.067–1.292  | 0.001   |
| High-density lipoprotein cholesterol   | 0.937 | 1.051–1.046  | 0.001   |
| Low-density lipoprotein cholesterol    | 0.955 | 0.726–1.256  | 0.74    |
| Lp(a)                                  | 1.248 | 1.055–1.550  | 0.045   |

Table 3. Logistic regression analysis of factors predicting for eGFR of 60–89 ml/min/1.73 m² in male and female subjects.

| Variables                              | Males | OR    | 95% CI       | P   | Females | OR    | 95% CI       | P   |
|----------------------------------------|-------|-------|--------------|-----|---------|-------|--------------|-----|
| Age                                    | 1.073 | 1.058–1.089 | <0.001     |     | 1.085   | 1.072–1.097 | <0.001     |
| History of hypertension (yes vs. no)   | 1.6   | 1.078–2.373 | 0.02       | 0.914 | 0.74–1.129 | 0.404   |
| History of diabetes mellitus (yes vs. no) | 0.936 | 0.599–1.463 | 0.773 | 0.836 | 0.645–1.084 | 0.177   |
| History of coronary heart disease or stroke (yes vs. no) | 1.095 | 0.662–1.811 | 0.723 | 0.999 | 0.762–1.309 | 0.993   |
| History of hepatitis (yes vs. no)      | 0.808 | 0.587–1.112 | 0.191 | 0.988 | 0.821–1.188 | 0.895   |
| History of cancer (1=yes vs. 0=no)     | 1.477 | 0.867–2.515 | 0.151 | 0.835 | 0.48–1.452 | 0.523   |
| Body mass index                        | 0.618 | 0.375–1.02  | 0.06       | 1.392 | 0.996–1.946 | 0.053   |
| Hemoglobin                             | 1.07  | 1.06–1.079  | <0.001     |     | 1.031   | 1.024–1.038 | <0.001     |
| Triglycerides                          | 1.443 | 1.065–1.955 | 0.018 | 1.229 | 1.078–1.401 | 0.002   |
| High-density lipoprotein cholesterol   | 0.789 | 0.409–1.52  | 0.479 | 0.47  | 0.282–0.784 | 0.004   |
| Low-density lipoprotein cholesterol    | 1.086 | 0.606–1.943 | 0.782 | 0.838 | 0.548–1.282 | 0.415   |
| Lp(a)                                  | 1.000 | 1.000–1.001 | 0.225 | 1.001 | 1.000–1.001 | 0.006   |
| Carotid atherosclerosis (yes vs. no)   | 0.71  | 0.4–1.26    | 0.241 | 0.799 | 0.631–1.012 | 0.063   |
and biochemical factors that are routinely assessed during routine health examinations can help identify individuals at higher risk of having CKD stage 2, in whom preventive interventions (such as drugs) could be started early and before symptoms appear [5–7].

The progression of CKD is inevitable [34,35]. GFR declines as a normal process of aging, but the rate of decline is heterogeneous among different individuals and a number of environmental and genetic factors are associated with this decline [20]. A community-based study of individuals >65 years of age showed a decline of 0.8–1.4 ml/min/1.73 m² per year [36], while another study showed that about 67% of healthy older individuals have significant loss of GFR over 10 years [37]. Hence, many patients with CKD stage 2 will probably progress to stage >3, hence the importance for proper identification of the patients.

In 2012, the US Preventive Services Task Force (USPSTF) and the American College of Physicians (ACP) stated that the evidence for CKD screening in asymptomatic individuals were inadequate and that there was no universal tool for CKD screening [38], but patients with diabetes or hypertension were not included in their analysis. The ACP later recommended against screening for CKD in asymptomatic individuals were inadequate [39], mainly because of the lack of high evidence level clinical trials on the risks and harms of CKD screening. On the other hand, the American Society of Nephrology (ASN) “strongly recommends regular screening for CKD, regardless of risk factors” [11]. Other organizations also support screening in individuals at higher risk of CKD [40–42]. Nevertheless, therapies are available to slow the progression of CKD stage 2 and delay the need for dialysis or kidney transplant and it has been shown that early management can improve patient prognosis [5–7], supporting the need for early diagnosis of even mild kidney impairment (CKD stage 2).

Kshirsagar et al. [43] reported that age, gender, anemia, hypertension, diabetes, history of cardiovascular disease, history of heart failure, and peripheral vascular disease could be used to predict the risk of GFR <60 ml/min/1.73 m². Using the Framingham Offspring Study, O’Séaghdha et al. [1] showed that age, diabetes, hypertension, proteinuria, and eGFR could be used to predict stage >3 CKD. The SCORED model uses age, gender, anemia, hypertension, diabetes, history of cardiovascular disease, history of heart failure, peripheral artery disease, and proteinuria to predict CKD [44]. Another clinical prediction model, based on age, body mass index, diastolic blood pressure, history of diabetes, and history of stroke, has been shown to predict CKD [45]. A previous study by our group showed that age, gender, and HDL-C were associated with eGFR <60 ml/min/1.73 m², while routine urinalysis showed

| Variables                                      | 18–45 years | 45–65 years |
|------------------------------------------------|-------------|-------------|
|                                              | OR  | 95% CI      | P    | OR  | 95% CI      | P    |
| Male gender                                   | 10.526 | 7.143–15.625 | < 0.001 | 5.025 | 3.831–6.579 | < 0.001 |
| Older age                                     | 0.988 | 0.654–1.492 | 0.953 | 1.194 | 0.974–1.463 | 0.088 |
| History of hypertension (yes vs. no)          | 1.039 | 0.555–1.943 | 0.906 | 1.247 | 0.965–1.612 | 0.092 |
| History of diabetes mellitus (yes vs. no)     | 0.968 | 0.282–3.33  | 0.959 | 1.161 | 0.77–1.751  | 0.476 |
| History of coronary heart disease or stroke (yes vs. no) | 0.925 | 0.548–1.561 | 0.769 | 1.011 | 0.731–1.396 | 0.949 |
| History of chronic kidney disease (yes vs. no) | 0.853 | 0.644–1.131 | 0.269 | ---   | ---         | ---   |
| History of cancer (1=yes vs. 0=no)            | 1.051 | 0.755–1.465 | 0.767 | 1.156 | 0.952–1.404 | 0.144 |
| Body mass index                               | 0.864 | 0.346–2.155 | 0.754 | 0.984 | 0.642–1.51  | 0.942 |
| Hemoglobin                                    | 0.989 | 0.589–1.661 | 0.966 | 0.992 | 0.73–1.349  | 0.96  |
| Blood cholesterol                             | 0.895 | 0.64–1.253  | 0.52  | ---   | ---         | ---   |
| Triglycerides                                  | 1.389 | 1.042–1.851 | 0.025 | 1.193 | 1.00–1.423  | 0.0498|
| High-density lipoprotein cholesterol          | 0.994 | 0.755–1.309 | 0.965 | 0.875 | 0.718–1.068 | 0.189 |
| Low-density lipoprotein cholesterol           | 0.89  | 0.624–1.271 | 0.521 | 0.838 | 0.654–1.073 | 0.161 |
| Lp(a)                                         | 0.946 | 0.682–1.313 | 0.737 | 1.066 | 0.843–1.347 | 0.595 |
| Carotid atherosclerosis (yes vs. no)          | 1.76  | 0.751–4.125 | 0.194 | 1.495 | 1.063–2.103 | 0.021 |

Table 4. Logistic regression analysis of factors predicting for eGFR of 60–89 ml/min/1.73 m² in subjects 18–45 and 45–65 years of age.
poor performance [46]. Nevertheless, these models can be used to predict stage >3 CKD, i.e. when CKD becomes symptomatic and significant kidney damage has already occurred.

In the present study, it was found that male gender, age, hemoglobin levels, triglycerides levels, HDL-C, Lp(a) levels, and carotid atherosclerosis were associated with eGFR 60–89 ml/min/1.73 m² among all subjects. When considering the gender and age subgroups, some variations were observed but cardiovascular risk factors, especially triglycerides levels, were globally associated with the risk of CKD stage 2. Those factors are generally associated with the metabolic syndrome, which has been shown to be associated with CKD [47–49]. Nevertheless, those results are generally supported by the previous models used to predict stage >3 CKD since a number of risk factors appears to be shared [1,43–45].

Previous studies examined the risk factors for CKD stage 2 in various populations worldwide [12–20]. Again, the identified factors were similar to those identified for more advanced CKD. In a Taiwanese population, Chang et al. [15] showed that the risk factors for CKD stage 2 were proteinuria, age, anemia, and poor blood pressure control for men, and poor glycemic control, poor blood pressure control, and family income for women. Another Taiwanese study showed that the presence of occult urine blood could predict the risk of CKD [18].

Importantly, diet and lifestyle factors are associated with the development of CKD and some of those factors are population-specific. Indeed, dyslipidemia among Chinese individuals is mainly manifested as high triglycerides and low HDL-C [23–25], and this pattern has been associated, among other factors, with the high consumption of peppers [26]. Previous studies from Japan showed that high triglyceride and low HDL-C levels were associated with declining eGFR [27–29]. This association was also observed in Chinese individuals [50,51]. Furthermore, carotid atherosclerosis has been shown to be associated with lower eGFR [30,31]. Taken together, those previous studies and the results presented here suggest that cardiovascular risk factors that are easily and routinely measured can predict declining eGFR in an Asian population. Nevertheless, since the exact patterns seem to vary among subgroups, additional studies are necessary to identify those patterns.

The present study is not without limitations. Although the sample size was large, it was from a single hospital serving a single geographical region of China. Since lifestyle and genetic factors vary considerably among different regions of China, additional studies are necessary to determine the exact risk factors for CKD in China. In addition, future studies should consider use of food questionnaires and additional biomarkers (such as inflammatory markers).

Conclusions

Factors that are routinely assessed during routine health examinations (male gender, age, hemoglobin levels, triglycerides levels, HDL-C, Lp(a) levels, and carotid atherosclerosis) can help identify individuals at higher risk of having CKD stage 2. The Chinese dyslipidemia is characterized by high triglycerides and low HDL-C and occurs in young and middle-aged individuals. Those factors could help identify individuals at higher risk for CKD stage 2 and who could benefit from preventive treatments.

Conflicts of interest

None.

References:

1. O’Searghda CM, Lyass A, Massaro JM et al: A risk score for chronic kidney disease in the general population. Am J Med, 2012; 125: 270–77
2. Hill NR, Fatoba ST, Oke JL et al: Global prevalence of chronic kidney disease – a systematic review and meta-analysis. PLoS One, 2016; 11: e0158765
3. Zhang L, Wang F, Wang L et al: Prevalence of chronic kidney disease in China: A cross-sectional survey. Lancet, 2012; 379: 815–22
4. McCullough K, Sharma P, Ali T et al: Measuring the population burden of chronic kidney disease: A systematic literature review of the estimated prevalence of impaired kidney function. Nephrol Dial Transplant, 2012; 27: 1812–21
5. Smart NA, Dieberg G, Ladhani M, Titus T: Early referral to specialist nephrology services for preventing the progression to end-stage kidney disease. Cochrane Database Syst Rev, 2014; 18: CD007333
6. Chan MR, Dall AT, Fletcher KE et al: Outcomes in patients with chronic kidney disease referred late to nephrologists: A meta-analysis. Am J Med, 2007; 120: 1063–70
7. Avorn J, Bohn RL, Levy E et al: Nephrologist care and mortality in patients with chronic renal insufficiency. Arch Intern Med, 2002; 162: 1002–6
8. Vassalotti JA, Li S, Chen SC, Collins AJ: Screening populations at increased risk of CKD: The Kidney Early Evaluation Program (KEEP) and the public health problem. Am J Kidney Dis, 2009; 53: S107–14
9. McGill JB, Brown WW, Chen SC et al: Kidney Early Evaluation Program (KEEP). Findings from a community screening program. Diabetes Educ, 2004; 30: 196–8, 200–2, 206
10. McClellan WM, Ramirez SP, Jurkovitz C: Screening for chronic kidney disease: Unresolved issues. J Am Soc Nephrol, 2003; 14: S81–87
11. Berns JS: Routine screening for CKD should be done in asymptomatic adults...selectively. Clin J Am Soc Nephrol, 2014; 9: 1988–92
12. Taal MW: Predicting renal risk in the general population: Do we have the right formula? Clin J Am Soc Nephrol, 2011; 6: 1523–25
13. Taal MW, Brenner BM: Predicting initiation and progression of chronic kidney disease: Developing renal risk scores. Kidney Int, 2006; 70: 1694–705
14. Echouffo-Tcheugui JB, Kengne AP: Risk models to predict chronic kidney disease and its progression: A systematic review. PLoS Med, 2012; 9: e1001344
15. Chang PY, Chien LN, Lin YF et al: Risk factors of gender for renal progression in patients with early chronic kidney disease. Medicine (Baltimore), 2016; 95: e4203
16. Hsu CY, Iribarren C, McCulloch CE et al: Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med, 2009; 169: 342–50
17. Dunkler D, Gao P, Lee SF et al: Risk Prediction for Early CKD in type 2 diabetes. Clin J Am Soc Nephrol, 2015; 10: 1371–79
18. Wu WC, Hsieh PC, Hu FK et al: Long-term predictive models of risk factors for early chronic kidney disease: A longitudinal study. Oncotarget, 2018; 9: 19745–52

19. Zomorrodian M, Khajavi-Rad A, Ayan A et al: Metabolic syndrome components as markers to prognosticate the risk of developing chronic kidney disease: Evidence-based study with 6492 individuals. J Epidemiol Community Health, 2015; 69: 594–98

20. Anderson S, Halter JB, Hazzard WR et al: Prediction, progression, and outcomes of chronic kidney disease in older adults. J Am Soc Nephrol, 2009; 20: 1199–209

21. Vupputuri S, Sandler DP: Lifestyle risk factors and chronic kidney disease. Ann Epidemiol, 2003; 13: 712–20

22. Stengel B, Tarver-Carr ME, Powe NR et al: Lifestyle factors, obesity and the risk of chronic kidney disease. Epidemiology, 2003; 14: 479–87

23. Shao X, Yang W, Shao X et al: The role of active brown adipose tissue (aBAT) in lipid metabolism in healthy Chinese adults. Lipids Health Dis, 2016; 15: 138

24. Pan L, Yang Z, Wu Y et al: The prevalence, awareness, treatment and control of dyslipidemia among adults in China. Atherosclerosis, 2016; 248: 2–9

25. Yang W, Xiao J, Yang Z et al: Serum lipids and lipoproteins in Chinese men and women. Circulation, 2012; 125: 2212–21

26. Xue Y, He T, Yu K et al: Association between spicy food consumption and lipid profiles in adults: A nationwide population-based study. Br J Nutr, 2017; 118: 144–53

27. Tsunaya K, Yoshida H, Nagata M et al: Association of hyperglycemia with the incidence and progression of chronic kidney disease and modification of the association by daily alcohol consumption. J Ren Nutr, 2017; 27: 381–94

28. Hayashi K, Takayama M, Abe T et al: Investigation of metabolic factors associated with eGFR decline over 1 year in a Japanese population without CKD. J Atheroscler Thromb, 2017; 24: 863–75

29. Tsunaya K, Yoshida H, Nagata M et al: Impact of the triglycerides to high-density lipoproteins cholesterol ratio on the incidence and progression of CKD: A longitudinal study in a large Japanese population. Am J Kidney Dis, 2015; 66: 972–83

30. Shimizu M, Furusyo N, Mitsumoto F et al: Subclinical carotid atherosclerosis and triglycerides predict the incidence of chronic kidney disease in the Japanese general population: Results from the Kyushu and Okinawa Population Study (KOPS). Atherosclerosis, 2015; 238: 207–12

31. Ishizaka N, Ishizaka Y, Toda E et al: Association between chronic kidney disease and carotid intima-media thickening in individuals with hypertension and impaired glucose metabolism. Hypertens Res, 2007; 30: 1035–41

32. Xue Y, He T, Shen YM, See LC: The Chinese version of the modification of diet in renal disease (MDRD) equation is a superior screening tool for chronic kidney disease among middle-aged Taiwanese than the original MDRD and Cockcroft-Gault equations. Biomed J, 2014; 37: 398–405

33. Atapour A, Elham K, Shahidi S et al: Modification of diet in renal disease and Cockcroft-Gaultformula accuracy in glomerular filtration rate estimation in Iranian adults. Adv Biomed Res, 2013; 2: 32

34. Sharaf El Din UA, Salem MM, Abdulazim DO: Stop chronic kidney disease progression: Time is approaching. World J Nephrol, 2016; 5: 258–73

35. Bauer C, Melamed ML, Hostetter TH: Staging of chronic kidney disease: Time for a course correction. J Am Soc Nephrol, 2008; 19: 844–46

36. Hemmelgarn BR, Zhang J, Manns B et al: Progression of kidney dysfunction in the community-dwelling elderly. Kidney Int, 2006; 69: 2155–61

37. Linderman RD, Tobin J, Shock NW: Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc, 1985; 33: 278–85

38. Moyer VA1; U.S. Preventive Services Task Force: Screening for chronic kidney disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med, 2012; 157: 567–70

39. Qaseem A, Hopkins RH Jr, Sweet DE, et al., Clinical Guidelines Committee of the American College of Physicians: Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: A clinical practice guideline from the American College of Physicians. Ann Intern Med, 2013; 159: 835–47

40. Executive summary: Standards of medical care in diabetes – 2013. Diabetes Care, 2013; 36(Suppl. 1): 54–10

41. Chobanian AV, Bakris GL, Black HR et al: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA, 2003; 289: 2560–72

42. Brosius FC 3rd, Hostetter TH, Kelepouris E et al: Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease: A science advisory from the American Heart Association Kidney And Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: Developing the collaboration with the National Kidney Foundation. Circulation, 2006; 114: 1083–87

43. Kshirsagar AV, Bang H, Bomback AS et al: A simple algorithm to predict incident kidney disease. Arch Intern Med, 2008; 168: 2466–73

44. Bang H, Vuppurturi S, Shoham DA et al: SCreening for Occult Renal Disease (SCORED): A simple prediction model for chronic kidney disease. Arch Intern Med, 2007; 167: 374–81

45. Chien KL, Lin HJ, Lee BC et al: A prediction model for the risk of incident chronic kidney disease. Am J Med, 2010; 123: 836–46e2

46. Xue N, Zhang X, Teng J et al: A cross-sectional study on the use of urinalysis for screening early-stage renal insufficiency. Nephron, 2016; 132: 335–41

47. Garofalo C, Borrelli S, Pacilio M et al: Hypertension and prehypertension and prediction of development of decreased GFR in the general population: A meta-analysis of cohort studies. Am J Kidney Dis, 2016; 67: 89–97

48. Chang Y, Ryu S, Choi Y et al: Metabolically healthy obesity and development of chronic kidney disease: A cohort study. Ann Intern Med, 2016; 164: 305–12

49. Ryu S, Chang Y, Woo HY et al: Time-dependent association between metabolic syndrome and risk of CKD in Korean men without hypertension or diabetes. Am J Kidney Dis, 2009; 53: 59–69

50. Zheng W, Qian G, Hao W et al: Cardiovascular metabolic risk factors and glomerular filtration rate: A rural Chinese population study. Lipids Health Dis, 2016; 15: 180

51. Wang Y, Qiu X, Lv L et al: Correlation between serum lipid levels and measured glomerular filtration rate in Chinese patients with chronic kidney disease. PLoS One, 2016; 11: e0163767